The European Medical Device Regulation (MDR), whose goals were initially supported by the European medtech industry, has been in force since May 2022. After half a year, the situation for the medium-sized medtech industry is devastating.
At the beginning of the Corona pandemic, many market participants were looking for investment opportunities in the health market. Companies like BioNTech, which had previously remained niche, became stock market stars. Can investors also profit from the transition to endemicity?
Medium-sized medical technology companies are facing many challenges in these geopolitically turbulent times: Supply chain problems, the MDR medical device regulation, digitalisation, energy shortages and rising refinancing costs due to the jump in interest rates. It’s good to have a solid capital base.
Digital health applications (DiGA) can improve medical care.
The healthcare sector has come under increased public scrutiny as a result of the Corona pandemic. M&A deals in the sector have reached a high level in 2021. Many lighthouse companies, however, choose the US market for the participation of an investor or the IPO. Funders like SHS Gesellschaft für Beteiligungsmanagement mbH also offer companies […]
Since 1993, the Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH has successfully developed and sold more than 68 companies from the medtech industry with capital and know-how. Read three success stories from our contribution to the Voelker brochure “Potentials MedTech 2022”, in which big names in medical technology have their say.
Consistent and reliable: the healthcare sector has been the innovation engine of the German and international economy for years
As an important future and economic factor, the healthcare industry has become more visible to the public in the past 20 months. There has also been significant movement in the market for healthcare investments. In the first half of 2021, the volume of M&A activities in the DACH region increased by around 20 % compared […]
In the car industry in particular, a robot-controlled production process already seems normal to us. But in medicine? Let’s take a look into the operating theatre of a urological centre in Germany in 2021!
Large investors often expect double-digit returns from private equity investments. Would this also be achievable for private investors? Risks and peculiarities should be very well known.
Advances in technology are enabling increasingly precise and individualised treatment of diseases.
The systemic use of health data enables the transformation from hypothesis-driven medicine to data-based medicine.
You need to load content from reCAPTCHA to submit the form. Please note that doing so will share data with third-party providers.
More Information